Lumida
/NVCR
⌘K
Novocure Ltd

Novocure Ltd

NVCR
$15.51USD+1.04%+0.16 today

MARKET CAP

1.8B

P/E (TTM)

FWD P/E

DAY RANGE

$15 – $16

52W RANGE

$10
$21

AI Summary

Stalk
TrimMedium

NVCR has broken key support in a Stage 4 environment, signaling accelerating downside. Medium-term bearish asymmetry is reinforced by support failure and lower highs/lows. Short-term, price is extended below declining EMAs and in oversold territory, suggesting risk of a countertrend bounce. Therefore, focus on trimming positions on rallies into resistance.

  • Q2 net revenue $184M (+16% YoY) driven by expanding patient base
  • Optune Pax launch for pancreatic cancer shows 74% disease control rate
  • Net loss $16M in Q2 and $136M YTD pressures cash flow
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$535.0M$537.8M$509.3M$605.2M$655.4M
YoY %+8.2%+0.5%-5.3%+18.8%+8.3%
P / Sales14.5x13.2x3.0x5.3x2.2x
EV / Sales15.5x14.4x4.1x6.5x2.8x
Gross Profit, Adj.$420.2M$423.0M$381.1M$468.0M$488.5M
YoY %+8.3%+0.7%-9.9%+22.8%+4.4%
Margin %78.5%78.6%74.8%77.3%74.5%
EV / Gross Profit19.7x18.3x5.4x8.4x3.7x
EBITDA, Adj.$-34.1M$-78.9M$-221.9M$-159.3M$-139.2M
YoY %-186.2%-131.5%-181.2%+28.2%+12.6%
Margin %-6.4%-14.7%-43.6%-26.3%-21.2%
EV / EBITDA-243.1x-98.2x-9.4x-24.7x-13.0x
EBIT$-44.3M$-89.5M$-232.9M$-170.5M$-153.8M
YoY %-245.8%-101.9%-160.1%+26.8%+9.8%
Margin %-8.3%-16.6%-45.7%-28.2%-23.5%
EV / EBIT-186.9x-86.5x-8.9x-23.1x-11.8x
Net Income$-58.4M$-92.5M$-207.0M$-168.6M$-136.2M
YoY %-394.6%-58.6%-123.7%+18.6%+19.2%
Net Margin-10.9%-17.2%-40.6%-27.9%-20.8%
EPS (GAAP)-$0.56-$0.88-$1.95-$1.56-$1.22
YoY %-411.1%-57.1%-121.6%+20.0%+21.8%